Strong alliance, commercial complementarity, Zhengda Tianqing and kangfang biological co operation ak-105

Yesterday evening, China biopharmaceutical announced that its subsidiary, Zhengda Tianqing, and kangfang bio co operated a company to jointly develop and recombine the humanized anti-PD-1 monoclonal antibody ak105, and vigorously promote the registration, listing and industrialization of the drug According to the joint venture contract, the registered capital of the joint venture company is RMB 689 million, of which Zhengda Tianqing will make capital contribution in cash of RMB 345 million, kangfang biology will make capital contribution in intangible assets with all the rights and interests of its ak105 project intellectual property and related technology (including any rights and interests in China and abroad), and technology will be invested They respectively hold 50% of the shares of the joint venture company It is worth noting that in the early stage of industrialization of ak105 project, the joint venture company will entrust kangfang biology to produce the drug; subsequently, with further optimization of production process, the production site can be transferred to Zhengda Tianqing Zhengda Tianqing has the exclusive right to sell ak105 project products of the joint venture company in China In addition, Zhengda Tianqing has the right to use the amino acid sequence of PD-1 antibody ak105 to develop other drug forms (including but not limited to bispecific or multispecific antibodies, antibody coupled drugs (ADC), etc.), and the rights and interests generated shall belong to Zhengda Tianqing alone Up to now, ak105 project has completed phase I climbing test in Australia and phase I clinical test in China, showing good safety, stable pharmacokinetic characteristics and promising preliminary anti-tumor effectiveness In China, ak105 project is carrying out the treatment of classic Hodgkin's lymphoma (phase II clinical study), metastatic nasopharyngeal carcinoma (phase II clinical study), and first-line chemotherapy In the future, more indications will be developed for the treatment of non scaly non-small cell lung cancer (phase III clinical study), combined chemotherapy for scaly non-small cell lung cancer (phase III clinical study), and combination of arotene hydrochloride and bevacizumab for the treatment of non resectable liver cancer (phase Ib / II clinical study) In addition, the ak105 project has obtained the approval of clinical trials in the United States This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.